Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
We observed a lower risk of a composite primary end-point event with tirzepatide than with placebo over a median of 2 years, in particular with respect to fewer worsening heart-failure events resulting in hospitalisation or use of intravenous drugs in an urgent care setting, the researchers said in the NEJM
Last reviewed: June 20, 2026 Last updated: June 20, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Your journey doesn't end with the prescription
International journal of molecular medicine, 44(1), 315
US$ 27.53
US$ 26.43
US$ 28.21
US$ 27.24
US$ 22.95
US$ 25.03
US$ 20.67
US$ 22.00
